The off-label use of drugs in the UK is relatively common in palliative care, in part because a drug's original marketing authorisation hasn't allowed for new routes and emerging novel indications for use. This case study explains the difficulties faced in complying with the wishes of a dying patient admitted to an adult hospice.
Freshwater, E., et al. 2017. Off-label drug use without evidence makes for a difficult decision-making process: a case study. European Journal of Palliative Care. 24 (6) p 274-276.
For a copy of the article please fill out the online request form